Dr. Reddy’s launches moxifloxacin HCl

News
Article

Dr. Reddy’s Laboratories has launched moxifloxacin HCl tablets, 400 mg, a therapeutic equivalent generic version of Avelox on March 4, following FDA approval.

 

Dr. Reddy’s Laboratories has launched moxifloxacin HCl tablets, 400 mg, a therapeutic equivalent generic version of Avelox on March 4, following FDA approval.

This fluoroquinolone is indicated for the treatment of adults with community-acquired pneumonia, acute exacerbations of chronic bronchitis, acute bacterial sinusitis, complicated skin and skin structure infections, pelvic inflammatory disease, and complicated intra-abdominal infections.

The product carries a warning that fluoroquinolones are associated with an increased risk of tendinitis and tendon rupture for patients of any age. There is a further increased risk in patients over 60 years of age, those taking corticosteroids, and individuals with kidney, heart, or lung transplants. Fluoroquinolones should not be used in patients with a history of myasthenia gravis as the drugs may exacerbate muscle weakness.

The brand name product had $195 million in U.S. sales for 2013, according to IMS Health.

Dr. Reddy’s generic moxifloxacin tablets, 400 mg, is available in bottle counts of 30.

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Recent Videos
Related Content
© 2025 MJH Life Sciences

All rights reserved.